Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

The target platelet count for ITP patients should be tailored to their lifestyle, bleeding history, and quality of life goals. A normal platelet count is not necessary, and different thresholds are appropriate for different patients (e.g., someone planning a ski trip versus a sedentary individual).

The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

Concerns about bone marrow fibrosis with TPO receptor agonists have been resolved. The effect is a reversible increase in reticulin fibrosis, not the permanent collagen fibrosis seen in myelofibrosis. It resolves upon stopping the drug, so routine bone marrow biopsies for monitoring are unnecessary.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

To minimize steroid toxicity, a thrombopoietin receptor agonist (TPORA) should be the immediate second-line therapy for ITP patients who fail their initial course of corticosteroids. There is no need to trial multiple other therapies before considering a TPORA.

While not standard of care, TPO receptor agonists like romiplostim can be used in the third trimester of pregnancy to raise platelet counts above 75,000 for epidural anesthesia. This is considered a reasonable option after critical fetal development is complete, avoiding the need for pre-pregnancy splenectomy.